Search

After the 1968 emigration, very few Jews remained in Poland, and even more miniscule was the number of "Jewish Jews." Since then the number has grown somewhat, and much of it is due to the process of de-assimilation; i.e., some people with Jewish ancestors raised in completely Polonized families began to recover, reclaim, and readapt their Jewish background. An analysis of this phenomenon is offered with a series of putative reasons for its occurrence. The individuals constituting the "products" of de-assimilation are the majority of Polish Jews today and form much of the current leadership. While individuals everywhere can strengthen their ties to the Jewish people and can experience teshuvah or another kind of "Judaization," the process of de-assimilation does not seem to be reducible to those moves. It begins with no Jewish identity, and is highly dependent on the attitudes and cultural trends in the majority society. It does not remove the de-assimilationists from the majority culture. The phenomenon is general and deserves to be studied as a sociological mechanism working in other cases of assimilation to a majority culture. In the Jewish case, it is especially dramatic. Probably the first example can be found in the evolution of the Marrano communities settled in Holland. The presence of de-assimilation seems to differentiate some European, first of all East European, communities from the globally dominant American and Israeli ones. Probably this rather new concept is needed to describe a significant part of the world of the Jews of twenty-first century Europe. [ABSTRACT FROM AUTHOR]

Glioblastoma is the most malignant central nervous system tumor, which represents 50% of all glial tumors. The understanding of glioma genesis, prognostic evaluation, and treatment planning has been significantly enhanced by the discovery of molecular genetic biomarkers. This study aimed to evaluate survival in patients with primary glioblastoma concerning O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation and other clinical factors. The study included 41 newly diagnosed glioblastoma patients treated from 2011 to 2014 in the 10th Military Research Hospital and Polyclinic, Poland. All patients underwent surgical resection followed by radiation and chemotherapy with alkylating agents. The MGMT promoter methylation was evaluated in all patients, and 43% were found to be methylated. In 26 and 15 cases, gross total resection and subtotal resection were conducted, respectively. Patients with a methylated MGMT promoter had a median survival of 504 days, while those without methylation had a median survival of 329 days. The group that was examined had a median age of 53. In a patient group younger than 53 years, those with methylation had significantly longer overall survival (639 days), compared to 433.5 days for patients without methylation. The most prolonged survival (551 days) was in patients with MGMT promoter methylation after gross total resection. The value of MGMT promoter methylation as a predictive biomarker is widely acknowledged. However, its prognostic significance remains unclear. Our findings proved that MGMT promoter methylation is also an essential positive prognostic biomarker. [ABSTRACT FROM AUTHOR]

The article features philosopher Andrzej Grzegorczyk. Born in Warsaw, Poland on August 22, 1922, Grzegorczyk simultaneously studied physics and philosophy at the clandestine Polish university located in Warsaw. He considered logic to be a part of the mathematical foundations of mathematics and he shared the view that logical studies should respect the deductive practice of science.

Epilepsy is a common consequence of brain tumors, occurring in 35 to 75% of cases. Here we evaluated the influence of epilepsy on the quality of life (QoL) of patients with malignant brain tumors (primary and metastatic) and assessed which areas of function are most affected by epilepsy and brain tumors. Sixty patients undergoing brain tumor surgery at the Neurosurgery Clinic of the 10th Military Research Hospital, Bydgoszcz, Poland (30 with epilepsy and 30 without epilepsy) were studied. Relationships between categorical variables were determined with Pearson's chi-squared test, while continuous data were analyzed with the Mann-Whitney U-test. A p value < 0.05 was considered statistically significant. A multiple regression model was used for multivariate analysis of QoL. Patients with epilepsy more frequently reported memory disorders as a problem in their daily life. There were trends towards greater impairments in social, professional, and family life, sports and recreational activities, and daily physical activities in brain tumor patients with epilepsy rather than those without epilepsy. Higher frequency and generalized seizures significantly and adversely influenced the ability of patients to leave home and drive vehicles, but a proportion of patients with frequent, generalized seizures continued to drive regardless. Patients with generalized seizures considered the adverse effects of taking medicines as significantly disruptive. Memory disorders significantly affect the QoL of patients with epilepsy, and the importance of stopping driving must be emphasized by all healthcare professionals.